Oliver Luxxe Assets LLC Has $2.20 Million Stock Position in Addus HomeCare Co. (NASDAQ:ADUS)

Oliver Luxxe Assets LLC raised its holdings in shares of Addus HomeCare Co. (NASDAQ:ADUS) by 244.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,512 shares of the company’s stock after purchasing an additional 11,723 shares during the period. Oliver Luxxe Assets LLC owned 0.09% of Addus HomeCare worth $2,197,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Redhawk Wealth Advisors Inc. acquired a new position in Addus HomeCare during the 3rd quarter valued at about $922,000. Inspire Investing LLC lifted its position in Addus HomeCare by 3.3% during the 3rd quarter. Inspire Investing LLC now owns 3,111 shares of the company’s stock valued at $414,000 after purchasing an additional 100 shares during the period. GAMMA Investing LLC lifted its position in Addus HomeCare by 25.7% during the 3rd quarter. GAMMA Investing LLC now owns 935 shares of the company’s stock valued at $124,000 after purchasing an additional 191 shares during the period. Handelsbanken Fonder AB lifted its position in Addus HomeCare by 20.8% during the 3rd quarter. Handelsbanken Fonder AB now owns 3,483 shares of the company’s stock valued at $463,000 after purchasing an additional 600 shares during the period. Finally, Sanctuary Advisors LLC acquired a new position in Addus HomeCare during the 2nd quarter valued at about $428,000. 95.35% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Addus HomeCare

In other news, EVP Michael D. Wattenbarger sold 21,917 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $133.29, for a total transaction of $2,921,316.93. Following the completion of the transaction, the executive vice president now directly owns 7,215 shares of the company’s stock, valued at $961,687.35. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Michael D. Wattenbarger sold 21,917 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $133.29, for a total value of $2,921,316.93. Following the completion of the sale, the executive vice president now owns 7,215 shares of the company’s stock, valued at approximately $961,687.35. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Esteban Lopez sold 500 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $127.50, for a total value of $63,750.00. Following the completion of the sale, the director now directly owns 3,366 shares of the company’s stock, valued at approximately $429,165. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,917 shares of company stock valued at $3,050,082 in the last ninety days. 4.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

ADUS has been the subject of a number of recent analyst reports. Macquarie reaffirmed an “outperform” rating and issued a $139.00 price target on shares of Addus HomeCare in a research note on Friday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $141.00 price target on shares of Addus HomeCare in a research note on Tuesday, September 3rd. Stephens reaffirmed an “overweight” rating and issued a $138.00 price target on shares of Addus HomeCare in a research note on Tuesday, August 6th. StockNews.com cut Addus HomeCare from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 7th. Finally, TD Cowen upped their price target on Addus HomeCare from $128.00 to $137.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $131.38.

Addus HomeCare Stock Performance

NASDAQ ADUS opened at $130.63 on Monday. The business has a 50 day simple moving average of $129.54 and a 200 day simple moving average of $117.34. Addus HomeCare Co. has a 52-week low of $78.35 and a 52-week high of $136.12. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of 32.41, a PEG ratio of 2.33 and a beta of 1.04.

Addus HomeCare (NASDAQ:ADUS) last issued its quarterly earnings results on Monday, August 5th. The company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.14. The company had revenue of $286.90 million during the quarter, compared to analysts’ expectations of $284.90 million. Addus HomeCare had a net margin of 6.18% and a return on equity of 9.81%. The business’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the business earned $0.94 EPS. On average, analysts predict that Addus HomeCare Co. will post 4.58 EPS for the current year.

About Addus HomeCare

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.